Clinical Scorecard: Geospatial Analysis of Cutaneous Leishmaniasis Lesions in Ethiopia Uncovers Unique Immune Response Patterns at the Tissue Level
At a Glance
Category
Detail
Condition
Cutaneous Leishmaniasis
Key Mechanisms
Inflammatory lesions with distinct immunopathological responses including epithelial hyperplasia, cytotoxicity, granulomatous inflammation, and fibrotic remodeling.
Target Population
Patients with cutaneous leishmaniasis in Ethiopia, predominantly young adults and children.
Care Setting
Clinical research setting in Ethiopia.
Key Highlights
Exploratory study using spatial transcriptomics on skin biopsies from CL patients.
Identified distinct immunopathological tissue responses in patients.
Current treatments for CL show 32-38% failure rates.
Facial lesions account for 45-97.6% of Ethiopian cases.
Study provides insights into the immune response at the tissue level.
Guideline-Based Recommendations
Diagnosis
Use paired lesional and non-lesional biopsies for accurate assessment.
Management
Sodium stibogluconate (SSG) is a common treatment, with follow-up assessments at one and six months.
Monitoring & Follow-up
Assess treatment response by reduction of lesion size and number of active lesions.
Risks
Treatment-related morbidity can compromise quality of life.
Patient & Prescribing Data
Five male patients with cutaneous leishmaniasis from Gondar city, Ethiopia.
Treatment response ranged from 50-99% at day 28 post-SSG.
Clinical Best Practices
Characterize immune responses at the lesional level for better understanding of disease heterogeneity.
Utilize spatial transcriptomics for mapping tissue responses.
